Uscom (ASX:UCM) - Share price, News & Analysis

UCM fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

UCM Stock Overview

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide.

Risk Analysis

Does not have a meaningful market cap (A$12M)

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$3M)

Uscom Competitors

Allegra Orthopaedics

ASX:AMT

AU$17.8m

Control Bionics

ASX:CBL

AU$18.5m

Resonance Health

ASX:RHT

AU$32.7m

Nova Eye Medical

ASX:EYE

AU$30.6m

Price History & Performance

Summary of all time highs, changes and price drops for Uscom
Historical stock prices
Current Share Price	AU$0.062
52 Week High	AU$0.15
52 Week Low	AU$0.056
Beta	-0.68
1 Month Change	-11.43%
3 Month Change	-27.06%
1 Year Change	-58.67%
3 Year Change	-40.95%
5 Year Change	-65.56%
Change since IPO	-97.42%

Shareholder Returns

	UCM	AU Medical Equipment	AU Market
7D	3.3%	-0.2%	0.5%
1Y	-58.7%	-18.3%	-8.8%

Return vs Industry: UCM underperformed the Australian Medical Equipment industry which returned -17.5% over the past year.

Return vs Market: UCM underperformed the Australian Market which returned -8.1% over the past year.

Price Volatility

Is UCM's price volatile compared to industry and market?
UCM volatility
UCM Average Weekly Movement	8.8%
Medical Equipment Industry Average Movement	11.5%
Market Average Movement	10.5%
10% most volatile stocks in AU Market	17.8%
10% least volatile stocks in AU Market	4.6%

Stable Share Price: UCM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: UCM's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	35	Rob Phillips	https://www.uscom.com.au

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company provides the SpiroSonic AIR, a digital home care spirometer which feeds digital lung function signals through a phone app; and Ventitest, a digital ultrasonic ventilator testing solution for testing ventilators.

Uscom Fundamentals Summary

How do Uscom's earnings and revenue compare to its market cap?
UCM fundamental statistics
Market Cap	AU$12.32m
Earnings (TTM)	-AU$1.60m
Revenue (TTM)	AU$3.42m

3.6x

P/S Ratio

-7.7x

P/E Ratio

Is UCM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
UCM income statement (TTM)
Revenue	AU$3.42m
Cost of Revenue	AU$215.69k
Gross Profit	AU$3.21m
Other Expenses	AU$4.80m
Earnings	-AU$1.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.008
Gross Margin	93.70%
Net Profit Margin	-46.70%
Debt/Equity Ratio	0%

How did UCM perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is UCM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UCM?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for UCM. This is calculated by dividing UCM's market cap by their current preferred multiple.
What is UCM's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	AU$12.32m

UCM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	-6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does UCM's PS Ratio compare to its peers?

UCM PS Ratio vs Peers

The above table shows the PS ratio for UCM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	4.7x
AMT Allegra Orthopaedics	3.3x	n/a	AU$17.8m
CBL Control Bionics	4.4x	40.0%	AU$18.5m
RHT Resonance Health	9x	n/a	AU$32.7m
EYE Nova Eye Medical	2.2x	13.0%	AU$30.6m
UCM Uscom	3.6x	n/a	AU$12.3m

Price-To-Sales vs Peers: UCM is good value based on its Price-To-Sales Ratio (3.6x) compared to the peer average (4.7x).

Price to Earnings Ratio vs Industry

How does UCM's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

Price-To-Sales vs Industry: UCM is good value based on its Price-To-Sales Ratio (3.6x) compared to the Australian Medical Equipment industry average (6.6x)

Price to Sales Ratio vs Fair Ratio

What is UCM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UCM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate UCM's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of UCM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate UCM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate UCM's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Uscom forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

18.3%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uscom has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine Uscom's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
Uscom competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Uscom performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

15.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: UCM is currently unprofitable.

Growing Profit Margin: UCM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: UCM is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.

Accelerating Growth: Unable to compare UCM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UCM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).

Return on Equity

High ROE: UCM has a negative Return on Equity (-23.98%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Uscom's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: UCM's short term assets (A$7.1M) exceed its short term liabilities (A$946.5K).

Long Term Liabilities: UCM's short term assets (A$7.1M) exceed its long term liabilities (A$1.3M).

Debt to Equity History and Analysis

Debt Level: UCM is debt free.

Reducing Debt: UCM has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UCM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: UCM has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 25.2% each year.

Discover healthy companies

Dividend

What is Uscom current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate UCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UCM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UCM's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as UCM has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average board tenure

CEO

Rob Phillips (69 yo)

no data

Tenure

AU$685,877

Compensation

Dr. Robert Allan Phillips, also known as Rob, Ph D.(Med), MPhil (Med), FASE, DMU, AMS, FIR, is the Founder of Uscom Limited and serves as its Chief Scientist. Dr. Phillips has been the Chief Executive Offi...

CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD478.03K) is above average for companies of similar size in the Australian market ($USD281.90K).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.

Board Members

Experienced Board: UCM's board of directors are considered experienced (4 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.5%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/10 00:00
End of Day Share Price	2022/08/09 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30